zuma-1: updated data and future prospects
Published 5 years ago • 110 plays • Length 3:32Download video MP4
Download video MP3
Similar videos
-
3:31
zuma-1 trial observations
-
1:44
comparison of zuma-1 and scholar-1 outcomes
-
1:34
zuma-1 update: safety data of axi-cel in patients with r/r dlbcl
-
2:09
zuma series update: zuma-1 and zuma-2
-
2:00
zuma-1 trial: fda approval and follow-up of car t-cell product axicabtagene ciloleucel
-
8:58
oh-my-cron! covid-19 omicron variant - how afraid do we need to be?
-
6:59
understanding the new variants
-
4:48
q&a about the sublineages of the covid-19 omicron variant
-
2:59
axi-cel in older patients: data from zuma-1 and clinical use
-
2:38
zuma-1 & scholar-1: comparison of outcomes in refractory dlbcl
-
2:48
zuma-1: safety and efficacy of axicabtagene in refractory non-hodgkin lymphoma patients
-
1:15
primary overall survival analysis of the zuma-7 trial
-
2:32
zuma-1 update: durable survival in r/r dlbcl patients treated with axi-cel
-
2:24
zuma-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; kte-c19) in patients with nhl
-
1:41
zuma-1: 3-year follow-up on axi-cel in lbcl patients
-
2:30
zuma-1: outcomes of car-t in older patients
-
2:00
long-term follow-up results of the zuma-1 trial of anti-cd19 car t-cells for non-hodgkin lymphoma
-
0:54
insights into the zuma-23 trial: axi-cel in frontline high-risk lbcl
-
2:19
zuma-3: identifying the optimal dose of axi-cel in r/r all
-
3:05
zuma-1, juliet and transcend trials: changing the treatment landscape for r/r nhl
-
1:52
zuma-1 safety management study: early use of steroids helps manage side effects
-
2:52
zuma-24 preliminary analysis of axi-cel in the outpatient setting in patients with r/r lbcl